JP2019531716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531716A5 JP2019531716A5 JP2019513015A JP2019513015A JP2019531716A5 JP 2019531716 A5 JP2019531716 A5 JP 2019531716A5 JP 2019513015 A JP2019513015 A JP 2019513015A JP 2019513015 A JP2019513015 A JP 2019513015A JP 2019531716 A5 JP2019531716 A5 JP 2019531716A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- seq
- peptides
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 206010028417 myasthenia gravis Diseases 0.000 claims description 24
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 18
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 229920002101 Chitin Polymers 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000002493 microarray Methods 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940098197 human immunoglobulin g Drugs 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- -1 porous strip Substances 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384896P | 2016-09-08 | 2016-09-08 | |
| US62/384,896 | 2016-09-08 | ||
| PCT/US2017/050521 WO2018049053A2 (en) | 2016-09-08 | 2017-09-07 | Peptides and uses thereof for diagnosing and treating myasthenia gravis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531716A JP2019531716A (ja) | 2019-11-07 |
| JP2019531716A5 true JP2019531716A5 (enExample) | 2020-10-08 |
| JP7169267B2 JP7169267B2 (ja) | 2022-11-10 |
Family
ID=61562129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513015A Active JP7169267B2 (ja) | 2016-09-08 | 2017-09-07 | 重症筋無力症を診断および治療するためのペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11422132B2 (enExample) |
| EP (1) | EP3512873B1 (enExample) |
| JP (1) | JP7169267B2 (enExample) |
| KR (1) | KR102501179B1 (enExample) |
| CN (1) | CN109996812A (enExample) |
| AU (1) | AU2017322312B2 (enExample) |
| CA (1) | CA3036130A1 (enExample) |
| WO (1) | WO2018049053A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7169267B2 (ja) | 2016-09-08 | 2022-11-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 重症筋無力症を診断および治療するためのペプチドおよびその使用 |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| MX2021013949A (es) * | 2019-05-13 | 2022-01-04 | Univ Pennsylvania | Composiciones y metodos de celulas de receptor de autoanticuerpo quimerico del receptor de acetilcolina. |
| WO2021236724A2 (en) * | 2020-05-20 | 2021-11-25 | Remd Biotherapeutics, Inc. | Human endothelin receptor a (etar) antagonist antibodies |
| CN112029880B (zh) * | 2020-09-15 | 2023-04-28 | 石家庄市人民医院(石家庄市第一医院、石家庄市肿瘤医院、河北省重症肌无力医院、石家庄市心血管病医院) | 用于重症肌无力的检测的微生物及应用 |
| WO2022063880A1 (en) | 2020-09-24 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of myasthenia gravis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3391831B2 (ja) * | 1993-01-13 | 2003-03-31 | 株式会社クラレ | 環状ペプチド |
| US20020081652A1 (en) * | 1997-05-07 | 2002-06-27 | Sara Fuchs | Recombinant fragments of the human acetylcholine receptor and their use for treatment of myasthenia gravis |
| EP1218502A2 (en) | 1999-09-15 | 2002-07-03 | Janssen Pharmaceutica N.V. | Nicotinic acetylcholine receptor : alpha10 subunit |
| US20050048066A1 (en) * | 2000-03-31 | 2005-03-03 | Shrikant Deshpande | Identification of potential immunodominant acetylcholine receptor alpha subunit |
| JP4283812B2 (ja) | 2006-01-06 | 2009-06-24 | 財団法人工業技術研究院 | 重症筋無力症の診断方法およびそのキット |
| WO2010014723A1 (en) * | 2008-07-29 | 2010-02-04 | The Board Of Regents Of The University Of Texas System | Methods and composition related to acetylcholine receptor conjugates |
| JP4495776B1 (ja) | 2009-07-30 | 2010-07-07 | 日本製薬株式会社 | 融合蛋白質 |
| JP7169267B2 (ja) | 2016-09-08 | 2022-11-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 重症筋無力症を診断および治療するためのペプチドおよびその使用 |
-
2017
- 2017-09-07 JP JP2019513015A patent/JP7169267B2/ja active Active
- 2017-09-07 KR KR1020197009929A patent/KR102501179B1/ko active Active
- 2017-09-07 CA CA3036130A patent/CA3036130A1/en active Pending
- 2017-09-07 AU AU2017322312A patent/AU2017322312B2/en not_active Ceased
- 2017-09-07 EP EP17849543.8A patent/EP3512873B1/en active Active
- 2017-09-07 CN CN201780064528.7A patent/CN109996812A/zh active Pending
- 2017-09-07 WO PCT/US2017/050521 patent/WO2018049053A2/en not_active Ceased
-
2019
- 2019-03-06 US US16/294,820 patent/US11422132B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531716A5 (enExample) | ||
| JP2024056703A5 (enExample) | ||
| JP5753775B2 (ja) | 化学合成した核酸の純度を測定する方法と組成物 | |
| JP2002521391A5 (enExample) | ||
| JP2002542157A5 (enExample) | ||
| Gerli et al. | Anti-ribosomal P protein antibodies | |
| JP2004512824A5 (enExample) | ||
| JP2006502416A5 (enExample) | ||
| US20120220534A1 (en) | Biomarker for neurodegeneration in neurological disease | |
| EP1881064A2 (en) | HCV-Anti-core monoclonal antibodies | |
| TR201806292T4 (tr) | Prokalsi̇toni̇ni̇n saptanmasi i̇çi̇n i̇mmünoloji̇k test | |
| JP6081699B2 (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP2006518991A5 (enExample) | ||
| JP2004532839A5 (enExample) | ||
| JP6938372B2 (ja) | ヒトｐ５３の直線状エピトープに結合する抗体及びその診断的応用 | |
| Hecker et al. | Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis | |
| JP2014518624A5 (enExample) | ||
| JP2015514707A5 (enExample) | ||
| CN110799212A (zh) | 特异性存在于调节性t细胞中的dkk1蛋白及其用途 | |
| Khalil et al. | Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments | |
| EP2001507A2 (en) | Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/diagnostic use | |
| O'Shannessy et al. | Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer | |
| JP5821198B2 (ja) | 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法 | |
| KR102339334B1 (ko) | 인간 메타뉴모바이러스(hMPV)의 항원 M의 특이적 단클론 항체 및 진단 방법에 있어서의 그 용도 | |
| JPH08502414A (ja) | ｐ５３蛋白断片とその疾患の検出およびモニタリングへの利用 |